WaveMan
WaveMan · Company
KYMR · Kymera Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

KYMR Kymera Therapeutics (KYMR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001815442
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
146
13F, latest reported quarter
Conversions, 180 days
11
Codes C/M, not in net · $1.2M priced

What the filings say about KYMR

Insiders, 180 days
-$400.3M net sold
8 sellers · 3% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$5.4M
3 notices

Kymera Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Kymera Therapeutics, Inc. insiders sold a net $400.3M of stock across 537 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Mainolfi Nello
Chief Executive Officer
SELL
2026-10-01 SEC
3,525
$392.8K
+3.1%
Context
  • 54 earlier Form 4 trades (code P or S) here by this insider (54 sales), the last on Jul 7, 2026.
  • The trade is 0.5% of the 693,043 shares held after it.
  • 1 other insider sold within 30 days.
  • 146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Mainolfi Nello sold about $392.8K of KYMR under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 146 funds added in the latest 13F quarter.
Mainolfi Nello
Chief Executive Officer
SELL
2026-10-01 SEC
5,506
$619.0K
+3.1%
Context
  • 54 earlier Form 4 trades (code P or S) here by this insider (54 sales), the last on Jul 7, 2026.
  • The trade is 0.8% of the 687,537 shares held after it.
  • 1 other insider sold within 30 days.
  • 146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Mainolfi Nello sold about $619.0K of KYMR under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 146 funds added in the latest 13F quarter.
Mainolfi Nello
Chief Executive Officer
SELL
2026-10-01 SEC
4,876
$552.2K
+3.1%
Context
  • 54 earlier Form 4 trades (code P or S) here by this insider (54 sales), the last on Jul 7, 2026.
  • The trade is 0.7% of the 682,661 shares held after it.
  • 1 other insider sold within 30 days.
  • 146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Mainolfi Nello sold about $552.2K of KYMR under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 146 funds added in the latest 13F quarter.
Mainolfi Nello
Chief Executive Officer
SELL
2026-10-01 SEC
7,601
$869.8K
+3.1%
Context
  • 54 earlier Form 4 trades (code P or S) here by this insider (54 sales), the last on Jul 7, 2026.
  • The trade is 1.1% of the 675,060 shares held after it.
  • 1 other insider sold within 30 days.
  • 146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Mainolfi Nello sold about $869.8K of KYMR under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 146 funds added in the latest 13F quarter.
Mainolfi Nello
Chief Executive Officer
SELL
2026-10-01 SEC
8,230
$949.7K
+3.1%
Context
  • 54 earlier Form 4 trades (code P or S) here by this insider (54 sales), the last on Jul 7, 2026.
  • The trade is 1.2% of the 666,830 shares held after it.
  • 1 other insider sold within 30 days.
  • 146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Mainolfi Nello sold about $949.7K of KYMR under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 146 funds added in the latest 13F quarter.
537 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 532 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$400.3M over 180 days
-$4.2M over 90 days
the lowest in Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
146 funds bought in last quarter
more than 81% of Pharma & Biotech
Revenue
-16.7% year over year
below 68% of Pharma & Biotech
Margin
-794.0% net margin
below 82% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
15.0% of the float short (float per yahoo 2026-10-26) · 12.0 days to cover · settled 2026-09-30
more than 78% of Pharma & Biotech
What changed in the last 30 days
Oct 1Chief Executive Officer Mainolfi Nello sold $3.4M under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Officer Mainolfi Nello filed to sell $3.4M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch KYMR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+98.5%12M
+0%+43%+85%+128%2025-102025-122026-022026-042026-062026-082026-10 2025-12-11 · BAKER FELIX bought $158.1M2026-06-26 · BIOTECHNOLOGY VALUE FUND II LP sold $89.2M2026-06-26 · BIOTECHNOLOGY VALUE FUND II LP sold $66.8M2026-06-26 · Booth Bruce sold $25.0M2025-12-11 · BAKER FELIX bought $14.4M2026-06-25 · Booth Bruce sold $13.5M2026-06-26 · BIOTECHNOLOGY VALUE FUND II LP sold $12.1M2026-06-24 · Booth Bruce sold $10.4M2026-06-25 · Booth Bruce sold $9.5M2025-12-08 · Mainolfi Nello sold $8.9M2026-06-17 · Booth Bruce sold $8.3M2025-12-10 · Booth Bruce sold $8.0M2026-06-25 · Booth Bruce sold $6.7M2026-03-02 · Booth Bruce sold $6.5M2026-07-07 · Mainolfi Nello sold $6.0M2026-06-30 · Jacobs Bruce N. sold $5.9M2026-06-18 · Booth Bruce sold $5.7M2026-06-22 · Booth Bruce sold $5.6M2026-06-26 · BIOTECHNOLOGY VALUE FUND II LP sold $5.5M2026-06-22 · Booth Bruce sold $5.2M2026-07-01 · Mainolfi Nello sold $5.1M2026-06-25 · Booth Bruce sold $4.9M2026-06-25 · Booth Bruce sold $4.5M2025-12-10 · Booth Bruce sold $4.4M2026-03-23 · Chadwick Jeremy G sold $4.1M2026-06-26 · Booth Bruce sold $3.6M2026-06-26 · Booth Bruce sold $3.5M2026-06-26 · Booth Bruce sold $3.2M2026-06-25 · Booth Bruce sold $3.2M2026-06-26 · Booth Bruce sold $3.0M2026-06-18 · Booth Bruce sold $3.0M2026-06-25 · Booth Bruce sold $2.9M2025-12-10 · Booth Bruce sold $2.8M2026-07-01 · Mainolfi Nello sold $2.8M2026-06-26 · Booth Bruce sold $2.6M2026-06-22 · Booth Bruce sold $2.6M2026-06-25 · Booth Bruce sold $2.3M2026-06-29 · Booth Bruce sold $2.1M2026-06-29 · Booth Bruce sold $2.1M2026-06-22 · Booth Bruce sold $2.0M2026-03-25 · Chadwick Jeremy G sold $2.0M2026-06-22 · Booth Bruce sold $1.9M2026-10-01 · Mainolfi Nello filed to sell $3.4M2026-09-04 · Brian Adams filed to sell $747.2K2026-09-02 · JEREMY CHADWICK filed to sell $1.3M2026-07-07 · Mainolfi Nello filed to sell $6.0M2026-07-02 · Mainolfi Nello filed to sell $9.1M2026-07-01 · NOAH GOODMAN filed to sell $388.6K2026-06-30 · BRUCE N. JACOBS filed to sell $8.4M2026-06-29 · Atlas Venture Fund X, LP filed to sell $7.2M2026-06-29 · Atlas Venture Opportunity Fund I, LP filed to sell $1.1M2026-06-26 · Atlas Venture Fund X, LP filed to sell $47.8M2026-06-26 · Atlas Venture Opportunity Fund I, LP filed to sell $6.7M2026-06-26 · BVF PARTNERS L P/IL filed to sell $189.9M2026-06-25 · Atlas Venture Fund X, LP filed to sell $48.0M2026-06-25 · Atlas Venture Opportunity Fund I, LP filed to sell $6.7M2026-06-25 · NOAH GOODMAN filed to sell $499.4K2026-06-24 · Atlas Venture Fund X, LP filed to sell $11.6M2026-06-24 · Atlas Venture Opportunity Fund I, LP filed to sell $1.6M2026-06-23 · Atlas Venture Fund X, LP filed to sell $122.8K2026-06-23 · Atlas Venture Opportunity Fund I, LP filed to sell $17.2K2026-06-22 · Atlas Venture Fund X, LP filed to sell $22.1M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns KYMR: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
12,349,256 sh
$1.4B
BAKER BROS. ADVISORS LP
8,657,242 sh
$992.7M
Avoro Capital Advisors LLC
7,474,747 sh
$857.1M
BlackRock, Inc.
5,538,210 sh
$635.1M
BVF INC/IL
3,872,052 sh
$444.0M

Congress trades in KYMR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

KYMR planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Mainolfi Nello
Filed 2026-10-01
$3.4M
Brian Adams
Filed 2026-09-04
$747.2K
JEREMY CHADWICK
Filed 2026-09-02
$1.3M
Mainolfi Nello
Filed 2026-07-07
$6.0M
Mainolfi Nello
Filed 2026-07-02
$9.1M

KYMR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$6.9M position · as of 2026-05-31
4.2%
Eventide Healthcare & Life Sciences Fund
$57.7M position · as of 2026-06-30
3.2%
AMG Frontier Small Cap Growth Fund
$2.1M position · as of 2026-07-31
2.3%
Harbor Human Capital Factor US Small Cap ETF
$3.8M position · as of 2026-07-31
2.2%
Baron Health Care Fund
$2.3M position · as of 2026-06-30
2.0%
Fidelity Disruptive Medicine ETF
$814.2K position · as of 2026-05-31
2.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
10 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
7
Phase 1
2 active
3
Phase 2
3 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$8.5M
$27.8M
$3.8M
+26%
+25%
2024
$15.4M
$19.8M
$5.4M
-35%
-7%
2023
$9.7M
$6.4M
$4.4M
-59%
-6%
2022
$6.9M
-$25.0M
$1.9M
-60%
-10%
2021
$11.6M
$12.6M
$3.3M
+2%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $400.3M sold by insiders over 180 days, 146 funds added last quarter, $5.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

KYMR financials

Revenue growth
-16.7%
XBRL, annual
Net margin
-794.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$105.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+307.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$238.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
+26.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+23.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-26.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-2.6%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$39.2M$47.1M$78.6M$46.8M
Operating income-$349.4M-$261.6M-$165.5M-$161.3M
Net income$311.4M$223.9M$147.0M$154.8M
EPS (diluted)-3.69-2.98-2.52-2.87
Operating cash flow-$232.9M-$194.5M-$102.8M-$153.1M
Cash$357.0M$120.3M$110.0M$68.4M
SEC XBRL, fiscal years, as known on 2026-10-27

KYMR Stock Sonar score 5/7 axes

Find similar shapesCompare

KYMR ranks highest on profitability (84th percentile) and institutional and government (81st), and lowest on insider conviction (1st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
84
Inputs
  • Return on equity+26.0% · 91 pct, sector of 545
  • Return on assets+23.3% · 93 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-26.8% · 69 pct, sector of 576
Growth
32
Inputs
  • Revenue growth, YoY-16.7% · 32 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
0
Inputs
  • Net Form 4 buying (codes P and S), 180d-$396.8M · 0 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
81
Inputs
  • Funds adding, latest quarter146 · 81 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
41
Inputs
  • Short interest, % of float+15.0% · 26 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+9.4% · 56 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

KYMR filings, in plain words

Are Kymera Therapeutics insiders buying or selling KYMR?

In the 180 days to 2026-10-27, Kymera Therapeutics insiders were net sellers, a net $400.3M across purchases and sales reported on Form 4, by 8 sellers.

Are there planned insider sales of KYMR?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $5.4M of stock; the latest, by Mainolfi Nello, was filed 2026-10-01.

Read the full summary

In the 180 days to 2026-10-27, Kymera Therapeutics insiders were net sellers of KYMR, a net $400.3M across purchases and sales reported on Form 4 by 8 sellers. 3% of the 176 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $5.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies